Oaktree Acquisition Corp. III Life Sciences (OACCW) Long-Term Investments (2024 - 2026)

Oaktree Acquisition Corp. III Life Sciences' Long-Term Investments history runs 3 years deep, the most recent figure standing at $203.4 million for Q1 2026.

• Quarterly Long-Term Investments rose 3.95% year-over-year to $203.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $203.4 million (up 3.95% YoY) and the FY2025 annual result came in at $201.6 million, up 4.12% from the prior year.
• Long-Term Investments was $203.4 million for Q1 2026 at Oaktree Acquisition Corp. III Life Sciences, up from $201.6 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $203.4 million in Q1 2026 and bottomed at $193.6 million in Q4 2024.
• A 3-year average of $198.6 million and a median of $198.7 million in 2025 frame the typical range for Long-Term Investments.
• Annual changes were most pronounced in 2025 — Long-Term Investments grew 4.12% — and 2026, when it rose 3.95%.
• Oaktree Acquisition Corp. III Life Sciences' Long-Term Investments stood at $193.6 million in 2024, then rose by 4.12% to $201.6 million in 2025, then gained by 0.92% to $203.4 million in 2026.
• Business Quant data shows OACCW's Long-Term Investments at $203.4 million in Q1 2026, $201.6 million in Q4 2025, and $199.8 million in Q3 2025.